Foghorn Therapeutics Inc.
NASDAQ:FHTX

Watchlist Manager
Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.
NASDAQ:FHTX
Watchlist
Price: 8.955 USD 1.19%
Market Cap: 495.5m USD
Have any thoughts about
Foghorn Therapeutics Inc.?
Write Note

Intrinsic Value

FHTX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one FHTX stock under the Base Case scenario is 7.023 USD. Compared to the current market price of 8.955 USD, Foghorn Therapeutics Inc. is Overvalued by 22%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

FHTX Intrinsic Value
7.023 USD
Overvaluation 22%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Foghorn Therapeutics Inc.

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for FHTX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about FHTX?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Foghorn Therapeutics Inc.

Provide an overview of the primary business activities
of Foghorn Therapeutics Inc..

What unique competitive advantages
does Foghorn Therapeutics Inc. hold over its rivals?

What risks and challenges
does Foghorn Therapeutics Inc. face in the near future?

Has there been any significant insider trading activity
in Foghorn Therapeutics Inc. recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Foghorn Therapeutics Inc..

Provide P/S
for Foghorn Therapeutics Inc..

Provide P/E
for Foghorn Therapeutics Inc..

Provide P/OCF
for Foghorn Therapeutics Inc..

Provide P/FCFE
for Foghorn Therapeutics Inc..

Provide P/B
for Foghorn Therapeutics Inc..

Provide EV/S
for Foghorn Therapeutics Inc..

Provide EV/GP
for Foghorn Therapeutics Inc..

Provide EV/EBITDA
for Foghorn Therapeutics Inc..

Provide EV/EBIT
for Foghorn Therapeutics Inc..

Provide EV/OCF
for Foghorn Therapeutics Inc..

Provide EV/FCFF
for Foghorn Therapeutics Inc..

Provide EV/IC
for Foghorn Therapeutics Inc..

Show me price targets
for Foghorn Therapeutics Inc. made by professional analysts.

What are the Revenue projections
for Foghorn Therapeutics Inc.?

How accurate were the past Revenue estimates
for Foghorn Therapeutics Inc.?

What are the Net Income projections
for Foghorn Therapeutics Inc.?

How accurate were the past Net Income estimates
for Foghorn Therapeutics Inc.?

What are the EPS projections
for Foghorn Therapeutics Inc.?

How accurate were the past EPS estimates
for Foghorn Therapeutics Inc.?

What are the EBIT projections
for Foghorn Therapeutics Inc.?

How accurate were the past EBIT estimates
for Foghorn Therapeutics Inc.?

Compare the revenue forecasts
for Foghorn Therapeutics Inc. with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Foghorn Therapeutics Inc. and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Foghorn Therapeutics Inc. against its competitors.

Analyze the profit margins
(gross, operating, and net) of Foghorn Therapeutics Inc. compared to its peers.

Compare the P/E ratios
of Foghorn Therapeutics Inc. against its peers.

Discuss the investment returns and shareholder value creation
comparing Foghorn Therapeutics Inc. with its peers.

Analyze the financial leverage
of Foghorn Therapeutics Inc. compared to its main competitors.

Show all profitability ratios
for Foghorn Therapeutics Inc..

Provide ROE
for Foghorn Therapeutics Inc..

Provide ROA
for Foghorn Therapeutics Inc..

Provide ROIC
for Foghorn Therapeutics Inc..

Provide ROCE
for Foghorn Therapeutics Inc..

Provide Gross Margin
for Foghorn Therapeutics Inc..

Provide Operating Margin
for Foghorn Therapeutics Inc..

Provide Net Margin
for Foghorn Therapeutics Inc..

Provide FCF Margin
for Foghorn Therapeutics Inc..

Show all solvency ratios
for Foghorn Therapeutics Inc..

Provide D/E Ratio
for Foghorn Therapeutics Inc..

Provide D/A Ratio
for Foghorn Therapeutics Inc..

Provide Interest Coverage Ratio
for Foghorn Therapeutics Inc..

Provide Altman Z-Score Ratio
for Foghorn Therapeutics Inc..

Provide Quick Ratio
for Foghorn Therapeutics Inc..

Provide Current Ratio
for Foghorn Therapeutics Inc..

Provide Cash Ratio
for Foghorn Therapeutics Inc..

What is the historical Revenue growth
over the last 5 years for Foghorn Therapeutics Inc.?

What is the historical Net Income growth
over the last 5 years for Foghorn Therapeutics Inc.?

What is the current Free Cash Flow
of Foghorn Therapeutics Inc.?

Discuss the annual earnings per share (EPS)
trend over the past five years for Foghorn Therapeutics Inc..

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Foghorn Therapeutics Inc.

Current Assets 271.2m
Cash & Short-Term Investments 267.4m
Other Current Assets 3.8m
Non-Current Assets 37.1m
PP&E 34.6m
Other Non-Current Assets 2.6m
Current Liabilities 56.8m
Accounts Payable 3.5m
Accrued Liabilities 19.8m
Other Current Liabilities 33.6m
Non-Current Liabilities 279.8m
Other Non-Current Liabilities 279.8m
Efficiency

Earnings Waterfall
Foghorn Therapeutics Inc.

Revenue
25.5m USD
Operating Expenses
-127.3m USD
Operating Income
-101.7m USD
Other Expenses
10.5m USD
Net Income
-91.2m USD

Free Cash Flow Analysis
Foghorn Therapeutics Inc.

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

FHTX Profitability Score
Profitability Due Diligence

Foghorn Therapeutics Inc.'s profitability score is 44/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional 3-Years Revenue Growth
Exceptional ROE
ROE is Increasing
44/100
Profitability
Score

Foghorn Therapeutics Inc.'s profitability score is 44/100. The higher the profitability score, the more profitable the company is.

FHTX Solvency Score
Solvency Due Diligence

Foghorn Therapeutics Inc.'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
53/100
Solvency
Score

Foghorn Therapeutics Inc.'s solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

FHTX Price Targets Summary
Foghorn Therapeutics Inc.

Wall Street analysts forecast FHTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FHTX is 16.32 USD with a low forecast of 9.09 USD and a high forecast of 21 USD.

Lowest
Price Target
9.09 USD
2% Upside
Average
Price Target
16.32 USD
82% Upside
Highest
Price Target
21 USD
135% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for FHTX?

Click here to dive deeper.

Dividends

Foghorn Therapeutics Inc.
does not pay dividends
Shareholder Yield

Current shareholder yield for FHTX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

FHTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Foghorn Therapeutics Inc. Logo
Foghorn Therapeutics Inc.

Country

United States of America

Industry

Biotechnology

Market Cap

491.2m USD

Dividend Yield

0%

Description

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. The company is headquartered in Cambridge, Massachusetts and currently employs 119 full-time employees. The company went IPO on 2020-10-23. The firm's Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is initially focused on oncology. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, which is evaluating in separate Phase I studies in metastatic uveal melanoma and relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company is also developing FHD-609, a protein degrader, to treat synovial sarcoma is in phase I study. The firm is also engaged in developing additional programs targeting populations that include selective BRM and selective ARID1B modulators. Foghorn Securities Corporation is its subsidiary.

Contact

MASSACHUSETTS
Cambridge
500 Technology Square, Suite 700
+16175863100.0
foghorntx.com

IPO

2020-10-23

Employees

119

Officers

President, CEO & Director
Mr. Adrian H. B. Gottschalk
Chief Scientific Officer
Dr. Steven F. Bellon Ph.D.
Chief Medical Officer
Dr. Alfonso Quintas Cardama M.D.
Founder & Member of Scientific Advisory Board
Dr. Gerald R. Crabtree M.d.
Chief Financial Officer
Mr. Kristian Humer M.B.A.
Chief Legal Officer
Mr. Michael J. LaCascia
Show More
Vice President of Corporate Development
Mr. Saurabh Sewak Ph.D.
Chief People Officer
Mr. Carlos Costa
Chief of Staff to the CEO
Ms. Karin Hellsvik
Chief Business Officer
Dr. Anna Rivkin Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one FHTX stock?

The intrinsic value of one FHTX stock under the Base Case scenario is 7.023 USD.

Is FHTX stock undervalued or overvalued?

Compared to the current market price of 8.955 USD, Foghorn Therapeutics Inc. is Overvalued by 22%.

Back to Top